{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:39:45Z","timestamp":1779280785282,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s11892-021-01416-1","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T10:02:47Z","timestamp":1638352967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Glycemic Control in Hospitalized Stroke Patients: A Review"],"prefix":"10.1007","volume":"21","author":[{"given":"Vishal N.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emory","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"issue":"1","key":"1416_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/jnis.2010.002865","volume":"3","author":"M DeGeorgia","year":"2011","unstructured":"DeGeorgia M, Patel V. Critical care management in acute ischemic stroke. J NeuroIntervent Surg. 2011;3(1):34\u20138.","journal-title":"J NeuroIntervent Surg"},{"issue":"suppl 1","key":"1416_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000107389","volume":"24","author":"B Fuentes","year":"2007","unstructured":"Fuentes B, Diez-Tejedor E. General care in stroke: relevance of glycemia and blood pressure levels. Cerebrovasc Dis. 2007;24(suppl 1):134\u201342.","journal-title":"Cerebrovasc Dis"},{"key":"1416_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1385\/NCC:5:2:153","volume":"5","author":"R Gilmore","year":"2006","unstructured":"Gilmore R, Stead L. The role of hyperglycemia in acute ischemic stroke. Neurocritical Care. 2006;5:153\u20138.","journal-title":"Neurocritical Care."},{"key":"1416_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1001\/archneur.58.8.1209","volume":"58","author":"N Kagansky","year":"2001","unstructured":"Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. Arch Neurol. 2001;58:1209\u201312.","journal-title":"Arch Neurol"},{"issue":"1","key":"1416_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/nyas.13872","volume":"143","author":"L Smith","year":"2018","unstructured":"Smith L, et al. Exposure to hypoglycemia and risk of stroke. Ann N Y Acad Sci. 2018;143(1):25\u201334.","journal-title":"Ann N Y Acad Sci"},{"key":"1416_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/STROKEAHA.108.519926","volume":"40","author":"Fuentes","year":"2009","unstructured":"Fuentes, et al. The prognostic value of capillary glucose levels in acute stroke: The Glycemia in Acute Stroke (GLIAS) Study. Stroke. 2009;40:562\u20138.","journal-title":"Stroke"},{"key":"1416_CR7","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1161\/01.STR.0000085087.41330.FF","volume":"34","author":"Baird","year":"2003","unstructured":"Baird, et al. Persistent poststroke hyperglycemia is independently associated with infarct volume expansion and worse clinical outcome. Stroke. 2003;34:2208\u201314.","journal-title":"Stroke"},{"key":"1416_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1474-4422(07)70080-7","volume":"6","author":"C Gray","year":"2007","unstructured":"Gray C, et al. Glucose\u2013potassium\u2013insulin infusions in the management of post-stroke hyperglycemia: The UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007;6:397\u2013406.","journal-title":"Lancet Neurol"},{"key":"1416_CR9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1161\/STROKEAHA.107.493544","volume":"39","author":"A Bruno","year":"2008","unstructured":"Bruno A, et al. Treatment of Hyperglycemia in Ischemic Stroke (THIS): a randomized pilot trial. Stroke. 2008;39:384\u20139.","journal-title":"Stroke"},{"key":"1416_CR10","doi-asserted-by":"crossref","unstructured":"Johnston K, et al for GRASP Investigators. Glucose Regulation in Acute Stroke Patients (GRASP) trial. A randomized pilot trial.\u00a0Stroke. 2009;40:3804\u20139.","DOI":"10.1161\/STROKEAHA.109.561498"},{"key":"1416_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jama.2019.9346","volume":"322","author":"K Johnston","year":"2019","unstructured":"Johnston K, et al. for SHINE Investigators. Intensive vs standard of treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke \u2013 the SHINE randomized clinical trial. JAMA. 2019;322:326\u201335.","journal-title":"JAMA."},{"key":"1416_CR12","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"Powers","year":"2019","unstructured":"Powers, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke. 2019;50:e344\u2013418.","journal-title":"Stroke"},{"key":"1416_CR13","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"S Marso","year":"2016","unstructured":"Marso S, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. NEJM. 2016;375:1834\u201344.","journal-title":"NEJM"},{"key":"1416_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. NEJM. 2019;381:841\u201351.","journal-title":"NEJM"},{"key":"1416_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12974-019-1638-6","volume":"16","author":"Y Shan","year":"2019","unstructured":"Shan Y, et al. The glucagon-like peptide 1 receptor agonist reduced inflammation and blood\u2013brain barrier breakdown in an astrocyte dependent manner in experimental stroke. J Neuroinflammation. 2019;16:242\u201362.","journal-title":"J Neuroinflammation."},{"issue":"s1","key":"1416_CR16","first-page":"S193","volume":"43","author":"ADA","year":"2020","unstructured":"ADA. Diabetes care in the hospital: standards of care in diabetes. Diab Care. 2020;43(s1):S193\u2013202.","journal-title":"Diab. Care."},{"key":"1416_CR17","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1210\/jc.2011-2098","volume":"97","author":"G Umpierrez","year":"2012","unstructured":"Umpierrez G. Management of hyperglycemia in the hospitalized patients in the non-critical care setting: an Endocrine Society Clinical Practice Guideline. JCEM. 2012;97:2011\u201398.","journal-title":"JCEM"},{"key":"1416_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1592\/phco.24.11.987.36131","volume":"24","author":"D Parra","year":"2004","unstructured":"Parra D, Legreid A, Beckey N, Reyes S. Metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous contrast media. Pharmacotherapy. 2004;24:987\u201393.","journal-title":"Pharmacotherapy"},{"key":"1416_CR19","first-page":"227","volume":"89","author":"M Namazi","year":"2018","unstructured":"Namazi M, et al. Is it necessary to discontinue metformin in diabetic patients with GFR > 60 ml\/min per 1.73 m2 undergoing coronary angiography: a controversy still exists? Acta Biomed. 2018;89:227\u201332.","journal-title":"Acta Biomed."},{"key":"1416_CR20","first-page":"CD002967","volume":"4","author":"SR Salpeter","year":"2010","unstructured":"Salpeter SR, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"1416_CR21","doi-asserted-by":"publisher","first-page":"9713","DOI":"10.1038\/s41598-018-27950-9","volume":"8","author":"F-F Li","year":"2018","unstructured":"Li F-F, et al. Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. Sci Rep. 2018;8(1):9713.","journal-title":"Sci Rep"},{"issue":"7","key":"1416_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/j.1875-9114.2011.01088.x","volume":"32","author":"CM Deusenberry","year":"2012","unstructured":"Deusenberry CM, et al. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy. 2012;32(7):613\u20137.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1416_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11892-017-0874-3","volume":"17","author":"JA Levine","year":"2017","unstructured":"Levine JA, Karam SL, Aleppo G. SGLT2-I in the hospital setting: diabetic ketoacidosis and other benefits and concerns. Curr Diab Rep. 2017;17(7):54.","journal-title":"Curr Diab Rep"},{"issue":"22","key":"1416_CR24","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"1416_CR25","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100(8):2849\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1416_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2337\/dc16-2724","volume":"40","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40(6):771\u20136.","journal-title":"Diabetes Care"},{"issue":"8","key":"1416_CR27","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.2337\/dc16-0885","volume":"39","author":"H Tang","year":"2016","unstructured":"Tang H, et al. Effect of sodium-glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2016;39(8):e123\u20134.","journal-title":"Diabetes Care"},{"issue":"8","key":"1416_CR28","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1210\/jc.2019-00139","volume":"104","author":"PS Hamblin","year":"2019","unstructured":"Hamblin PS, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019;104(8):3077\u201387.","journal-title":"J Clin Endocrinol Metab"},{"key":"1416_CR29","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","volume":"122","author":"A Scheen","year":"2018","unstructured":"Scheen A. Cardiovascular effects of new oral glucose-lowering agents. Circ Res. 2018;122:1439\u201359.","journal-title":"Circ Res"},{"issue":"14","key":"1416_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"14","key":"1416_CR31","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"1416_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2213-8587(16)30402-8","volume":"5","author":"FJ Pasquel","year":"2017","unstructured":"Pasquel FJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1416_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.298.2.194","volume":"298","author":"RE Amori","year":"2007","unstructured":"Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194\u2013206.","journal-title":"JAMA"},{"issue":"3","key":"1416_CR34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/CCM.0000000000000035","volume":"42","author":"P Galiatsatos","year":"2014","unstructured":"Galiatsatos P, et al. The glucoregulatory benefits of glucagon-like peptide-1 (7\u201336) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med. 2014;42(3):638\u201345.","journal-title":"Crit Care Med"},{"issue":"5","key":"1416_CR35","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","volume":"100","author":"GG Sokos","year":"2007","unstructured":"Sokos GG, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100(5):824\u20139.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1416_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4158\/EP12196.OR","volume":"19","author":"M Abuannadi","year":"2013","unstructured":"Abuannadi M, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract. 2013;19(1):81\u201390.","journal-title":"Endocr Pract"},{"issue":"8","key":"1416_CR37","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962\u20135.","journal-title":"Circulation"},{"key":"1416_CR38","first-page":"156","volume":"96","author":"K Sheahan","year":"2020","unstructured":"Sheahan K, Wahlberg E, Gilbert M. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. BMJ. 2020;96:156\u201361.","journal-title":"BMJ"},{"key":"1416_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","volume":"50","author":"B Sinha","year":"2019","unstructured":"Sinha B, Ghosal S. Meta-analysis of the effects of DPP-4 inhibitors, SLGT-2 inhibitors, and GLP-1 receptor analogues on cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;50:8\u201316.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1416_CR40","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1210\/jc.2005-2220","volume":"91","author":"TJ Little","year":"2006","unstructured":"Little TJ, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91(5):1916\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1416_CR41","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1186\/cc7874","volume":"13","author":"AM Deane","year":"2009","unstructured":"Deane AM, et al. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomized double-blind placebo-controlled cross over study. Crit Care. 2009;13(3):R67.","journal-title":"Crit Care"},{"issue":"1","key":"1416_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s13054-018-2197-4","volume":"22","author":"AH Hulst","year":"2018","unstructured":"Hulst AH, et al. Systematic review of incretin therapy during peri-operative and intensive care. Crit Care. 2018;22(1):299.","journal-title":"Crit Care"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-021-01416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-021-01416-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-021-01416-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T13:57:20Z","timestamp":1676037440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-021-01416-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1416"],"URL":"https:\/\/doi.org\/10.1007\/s11892-021-01416-1","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"27 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards, including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}],"article-number":"48"}}